MESS-study MRSA Eradication Study Skåne
- Conditions
- Throatcarriers of MRSA
- Interventions
- Drug: Rifampin+Clindamycine or Trimehoprimsulfa
- Registration Number
- NCT01269541
- Lead Sponsor
- Region Skane
- Brief Summary
The purpose of this study is to determine whether systemic antibiotic treatment with rifampicin and clindamycine or trimethoprim-sulfa in addition to topical treatment with mupirocin is more effective than only topical treatment to eradicate MRSA in throatcarriers
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 69
Colonized with MRSA in the throat Older than 5 years MRSA-bacteria sensitive for Rifampicin and Clindamycine or Trimethoprimsulfa -
Allergy to the studymedication Healthcareworkers Pregnancy Active infection with MRSA Immunosuppression Treatment with other antibiotic during the studyperiod
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Mupirocin Rifampin+Clindamycine or Trimehoprimsulfa Topical treatment Rifampicin+Clindamycine or Trimethoprimsulfa Rifampin+Clindamycine or Trimehoprimsulfa Rifampicin 10 mg/kgx1xVII Clindamycine 300 mgx3xVII Trimethoprimsulfa 400mg/80mg 2x2 Mupirocin Mupirocin Topical treatment
- Primary Outcome Measures
Name Time Method Culture for MRSA after 6 months
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (6)
Kristianstad hospital
🇸🇪Kristianstad, Skåne, Sweden
Örebro university hospital
🇸🇪Örebro, Sweden
SUS Malmö
🇸🇪Malmö, Skåne, Sweden
Helsingborg hospital
🇸🇪Helsingborg, Skåne, Sweden
Karolinska university hospital
🇸🇪Stockholm, Sweden
Infectious department SUS Lund
🇸🇪Lund, Skåne, Sweden